期刊文献+

顺铂和紫杉醇对CIK细胞杀伤食管癌细胞活性的影响及其分子机制研究 被引量:19

Effect of cisplatin and paclitaxel on the cytotoxicity of cytokine-induced killer cells on esophagus carcinoma and its molecular mechanisms
下载PDF
导出
摘要 目的:研究紫杉醇、顺铂对人食管癌EC9706细胞NKG2D配体表达及CIK细胞杀伤活性的影响,探讨相关分子机制。方法:MTT法测定紫杉醇、顺铂对EC9706细胞的24 h半数抑制浓度(IC50)。流式细胞仪检测1/2 IC50浓度紫杉醇、顺铂作用前、后EC9706细胞NKG2D配体的表达。乳酸脱氢酶释放法检测效靶比20:1、30:1时,CIK细胞对1/2 IC50浓度紫杉醇、顺铂作用前、后EC9706细胞的杀伤活性。荧光定量PCR法检测1/2 IC50浓度紫杉醇、顺铂作用EC9706细胞24 h前、后DNA损伤修复基因(ATM、ATR、CHK1、CHK2、P53)表达的变化。结果:紫杉醇、顺铂的24 h半数抑制浓度分别为10、5μg/m L。1/2 IC50浓度紫杉醇作用24 h后,EC9706细胞MICB、ULBP2、ULBP3表达均明显增强(P<0.05),MICA、ULBP1表达无显著性变化(P>0.05);1/2 IC50浓度顺铂作用24 h后,EC9706细胞MICA、MICB、ULBP2、ULBP3表达均明显增强(P<0.05),ULBP1表达无显著性变化(P>0.05)。效靶比20:1、30:1时,CIK细胞对1/2 IC50浓度紫杉醇、顺铂作用后的EC9706细胞的杀伤活性均明显增强(P<0.05)。1/2 IC50浓度紫杉醇作用24 h后,DNA损伤修复基因表达均无显著性变化(P>0.05);1/2 IC50浓度顺铂作用24 h后,ATM、ATR、CHK1、CHK2基因表达均明显增加(P<0.05),P53基因表达无显著性变化(P>0.05)。结论:顺铂、紫杉醇均可增强CIK细胞的杀伤活性,其分子机制可能与激活DNA损伤修复基因,进而增加NKG2D配体表达有关。 Objective:To explore the effect of paclitaxel (PTX) and cisplatin (DDP) on the expression of NKG2D ligands of hu-man esophagus carcinoma cell EC9706 and on the cytotoxicity of cytokine-induced killer (CIK) cells, as well as to discuss its molecu-lar mechanisms. Methods: The half maximal inhibitory concentration (IC50) values of PTX and DDP against EC9706 cells for 24 h were measured by MTT assay. The expression levels of NKG2D ligands (MICA, MICB, ULBP1, ULBP2, and ULBP3) on the EC9706 cell surface before and after 24 h culture with 1/2 IC50 of PTX or DDP were assayed by flow cytometry. Cytotoxicity of CIK cells against EC9706 cells before and after 24 h culture with 1/2 IC50 PTX or DDP was analyzed by lactate dehydrogenase release assay at an effector to target cell ratio (E:T) of 20:1 and 30:1, respectively. The expression levels of DNA damage repair genes (ATM, ATR, CHK1, CHK2, and p53) of EC9706 cells before and after 24 h incubation with 1/2 IC50 PTX or DDP were detected by quantitative fluorescent PCR. Results:The IC50 values of PTX and DDP were 10 and 5μg/mL, respectively. MICB, ULBP2, and ULBP3 on EC9706 cells were upregulated after 24 h culture with 1/2 IC50 PTX (P〈0.05), and the expression levels of MICA, MICB, ULBP2, and ULBP3 were higher after 24 h culture with 1/2 IC50 DDP (P〈0.05). Cytotoxicity of CIK cells against EC9706 cells cultured with 1/2 IC50 of PTX or DDP at E:T of 20:1 and 30:1 was significantly enhanced compared with those untreated (P〈0.05). The expression levels of DNA damage repair genes did not significantly increase after 24 h treatment with 1/2 IC50 PTX (P〉0.05), whereas ATM, ATR, CHK1, and CHK2 were over-expressed after 24 h treatment with 1/2 IC50 DDP (P〈0.05). Conclusion:PTX or DDP can enhance the susceptibility of EC9706 cells to CIK cell-mediated lysis by upregulating the expression of NKG2D ligands through activating DNA damage repair genes.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2015年第12期608-613,共6页 Chinese Journal of Clinical Oncology
基金 河南省科技计划攻关项目(编号:112102310126)资助~~
关键词 食管癌 紫杉醇 顺铂 细胞因子诱导的杀伤细胞 NKG2D配体 DNA损伤修复基因 esophagus carcinoma paclitaxel cisplatin cytokine-induced killer cells NKG2D ligands DNA damage repair genes
  • 相关文献

参考文献16

  • 1梅家转,赵继智,杨广英,高方方,刘桂举.食管癌组织中主要组织相容性复合体-I类分子链相关蛋白A/B表达及其临床意义[J].中华肿瘤杂志,2012,34(10):745-747. 被引量:2
  • 2梅家转,刘桂举,张晓娟,赵继智.IL-12增强CIK细胞对食管癌EC9706细胞的杀伤活性[J].中国肿瘤生物治疗杂志,2013,20(2):197-200. 被引量:10
  • 3Wang WJ, Oam SH, ZhangJW, et al. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D li- gands and MHC class Ⅰ[J]. Asian PacJ Cancer Prey, 2014, 15(22):9667-9672.
  • 4Leung WH,Vong Q P, Lin W, et al. Modulation of NKG2D li- gand expression and metastasis in tumors by spironolactone via RXR3, activation[J].J Exp Med, 2013, 210(12):2675-2692.
  • 5Cerbolfi C, Fionda C, Soriani A, et al. The DNA Damage Re- sponse: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells[J]. Front Immunol, 2014, 4:508.
  • 6张晓娟,梅家转,赵继智,冯睿婷,刘桂举.顺铂与CIK细胞对A549细胞杀伤协同作用机制的初步研究[J].中华肿瘤防治杂志,2013,20(16):1229-1231. 被引量:5
  • 7梅家转,刘桂举,李瑞君,栗敏,张晓娟.IL-15上调NKG2D表达对CIK细胞杀伤活性的增强效应[J].肿瘤防治研究,2011,38(5):495-497. 被引量:15
  • 8Beano A, Signorino E, Evangelista A, et al. Correlation between NK function and response to trastuzumab in metastatic breast can- cer patients[J].J Transl Med, 2008, 6:25.
  • 9Boissel N, Rea D, Tieng V, et al. BCR/ABL oncogene directly controls MHC class Ichain-related molecule A expression in chronicmyelo genous leukemia[J]. Immunol, 2006, 176(8):5108- 5116.
  • 10Morisaki T, Hirano T, Koya N, et al .NKG2D-directed cytokine- activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors[J]. Anti- cancer Res, 2014, 34(8):4529-4538.

二级参考文献55

  • 1梅家转,郭坤元,魏红,梅常红.不同肿瘤细胞表面MICA的表达及NK细胞杀伤活性的研究[J].中国免疫学杂志,2007,23(1):34-37. 被引量:16
  • 2Nausch N, Cerwenka A. NKG2D ligands in tumor immunity [J]. Oncogene, 2008, 27(45):5944- 5958.
  • 3Sutherland CL, Rabinovich B, human ligands of the NKG2D Chalupny NJ, et al. ULBPs, receptor, stimulate tumor im- munity with enhancement by IL-15[J]. Blood, 2006, 108(4) 1313-1319.
  • 4Introna M, Borleri G, Conti E,et al. Repeated infusions of do- nor derived cytokine induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study[J]. Haematologica, 2007, 92(7):952- 959.
  • 5Kim HM, Lim J, Kang JS, et al. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenogralt model [J]. Int Immunopharmacol, 2009, 9 (3):375-380.
  • 6Rowley J, Monie A, Hung CF, et al. Inhibition of tumor growth by NK1.1 +cells and CD8 + T cells activated by IL-15 through receptorβ/common γ signaling in trans [J]. J Immu- nol, 2008, 181(12):8237 -8247.
  • 7Dubois S, Patel HJ, Zhang M, et al. Preassociation of IL-15 with IL -15R α-IgG1- Fc enhances its activity on proliferation of NK and CD8 + /CD44 high T ceils and its antitumor action [J].J Immunol, 2008, 180(4) : 2099-2106.
  • 8Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses[J], Immunol Rev, 2010, 235 (1) : 267-285.
  • 9Introna M, Franceschetti M, Ciocca A, et al. Rapid and mas- sive expansion of cord blood-derived eytokine-induced killer cells: an innovative proposal for the treatment of leukemia re- lapse after cord blood transplantation[J]. Bone Marrow Trans- plant, 2006, 38(9):621-627.
  • 10Ayello J, van de Ven C, Cairo E, et al. Characterization of natural killer and natural killer like T ceils derived from ex vi- vo expanded and activated cord blood mononuclear cells: impli- cations for adoptive cellular immunotherapy[J]. Exp Hema- tol, 2009, 37(10): 1216- 1229.

共引文献25

同被引文献172

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1469
  • 2王锡林,生梦飞,曲震.紫杉醇和卡铂方案治疗中晚期乳腺癌的临床疗效[J].中国肿瘤临床与康复,2005,12(2):171-173. 被引量:4
  • 3Cooper JS,Guo MD,Herskovic A,et al.Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial(RTOG 85-01).Radiation Therapy Oneology Group[J].JAMA,1999,28l(17):1623-1627.
  • 4Tomas SM,Grandis JR.Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation[J].Cancer Treat Rev,2004,30(3):255-268.
  • 5Safran H,Suntharalingam M,Dipetrillo T,et al.Cetuximab with concurrent chemoradiation for esophagogastric cancer:assessment of toxicity[J].Int J Radiat Oncol Biol Phys,2008,70(2):391-395.
  • 6Shimizu T, Saijo N. Common toxicity criteria: version 2.0,an improved reference for grading the adverse reaction of cancer treatment[J]. Nihon Rinsho, 2003, 61(6): 937-942.
  • 7Agrawal A, Purandare N, Shah S, et al. Response assess- ment in metronomic chemotherapy: RECIST or PERCIST? [J]. Indian J Nucl Med. 2014. 29: 74-80.
  • 8Furuse KF, Kaw ahara M, Nishikawa H, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer[J]. J Clin Oncol, 1999, 17: 2692-2692.
  • 9Solomon B, Ball DL, Richardson G, et al. Phase I/II study of concurrent twice weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer[J]. Lung Cancer, 2003, 41(3): 353-361.
  • 10Takayama K, Inoue K, Tokunaga S, et al. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non small cell lung cancer: LOGIK0401[J]. Cancer Chemoth Pharma, 2013, 72(6): 1353-1359.

引证文献19

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部